Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Clinical diagnosis (ADIS-5) |
The Anxiety and Related Disorders Interview Schedule for DSM-5 (ADIS-5; Brown & Barlow, 2014) will be used to confirm a diagnosis of an anxiety disorder or MDD and establish the number of episodes, onset age, and potential comorbid disorders. The interview will also be used to confirm that none of the above listed reasons for exclusion are present (e.g., bipolar disorder, current or past psychosis). |
Baseline only |
|
Other |
Objective cognitive function - processing speed (TMT-A) |
Trail Making Test part A (TMT-A; Reitan, 1958). |
Baseline only |
|
Other |
Objective cognitive function - processing speed (WAIS-IV coding) |
Wechsler Adult Intelligence Scale - Fourth Edition, Coding (WAIS-IV coding; Wechsler, 2008). |
Baseline only |
|
Other |
Objective cognitive function - attention and working memory (WAIS-IV Digit span) |
Wechsler Adult Intelligence Scale - Fourth Edition, Digit span (WAIS-IV Digit span; Wechsler, 2008). |
Baseline only |
|
Other |
Objective cognitive function - executive function (COWAT) |
Controlled Oral Word Association Test (COWAT; Harrison et al., 2000). |
Baseline only |
|
Other |
Objective cognitive function - executive function (TMT-B) |
Trail Making Test part B (TMT-B; Reitan, 1958). |
Baseline only |
|
Other |
Objective cognitive function - executive function (STROOP) |
The Stroop Color and Word Test (STROOP; Stroop, 1935). |
Baseline only |
|
Other |
Objective cognitive function - premorbid intellectual abilities (WAIS-IV Information) |
Wechsler Adult Intelligence Scale - Fourth Edition, Information (WAIS-IV Information; Wechsler, 2008) will be included to control for premorbid intellectual abilities. |
Baseline only |
|
Primary |
Depressive symptoms (PHQ-9) |
Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000). |
Development from pre-treatment to post-treatment (6 weeks) |
|
Primary |
Anxiety symptoms (BAI) |
Beck's Anxiety Inventory (BAI; Beck et al., 1988; Beck & Steer, 1991). |
Development from pre-treatment to post-treatment (6 weeks) |
|
Primary |
Symptoms of generalized anxiety disorder (GAD-7) |
The General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006). |
Development from pre-treatment to post-treatment (6 weeks) |
|
Primary |
Symptoms of social anxiety disorder (SIAS) |
The Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998). |
Development from pre-treatment to post-treatment (6 weeks) |
|
Primary |
Symptoms of panic disorder (PDSS-SR) |
The Panic Disorder Severity Scale - Self-Report Version (PDSS-SR; Houck et al., 2002). |
Development from pre-treatment to post-treatment (6 weeks) |
|
Secondary |
Depressive symptoms (PHQ-9) |
Patient Health Questionnaire-9 (PHQ-9; Kroenke et al., 2001; Spitzer et al., 1999; Spitzer et al., 2000). |
Development from pre-treatment through 3-month follow-up |
|
Secondary |
Anxiety symptoms (BAI) |
Beck's Anxiety Inventory (BAI; Beck et al., 1988; Beck & Steer, 1991). |
Development from pre-treatment through 3-month follow-up |
|
Secondary |
Symptoms of generalized anxiety disorder (GAD-7) |
The General Anxiety Disorder-7 (GAD-7; Spitzer et al., 2006). |
Development from pre-treatment through 3-month follow-up |
|
Secondary |
Symptoms of social anxiety disorder (SIAS) |
The Social Interaction Anxiety Scale (SIAS; Mattick & Clarke, 1998). |
Development from pre-treatment through 3-month follow-up |
|
Secondary |
Symptoms of panic disorder (PDSS-SR) |
The Panic Disorder Severity Scale - Self-Report Version (PDSS-SR; Houck et al., 2002). |
Development from pre-treatment through 3-month follow-up |
|
Secondary |
Quality of life (WHO-5) |
The World Health Organization (WHO)-5 questionnaire (Bech, 1999; Topp et al., 2015). |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Rumination (RRS brooding subscale) |
The Ruminative Response Scale (RRS) brooding subscale (Treynor et al., 2003). |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Worry (PSWQ) |
The Penn State Worry Questionnaire (PSWQ; Meyer et al., 1990). |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Worry (AWS) |
For in-session questionnaires, the Ambulatory Worry Scale (AWS; Kramer et al., 2021) will be used because it has been specially developed to evaluate state variations in worry. |
Session by session development during the 6 weeks of active treatment |
|
Secondary |
Decentering (EQ decentering subscale) |
The Experiences Questionnaire (EQ) decentering subscale (Fresco et al., 2007). |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Reappraisal (ERQ) |
Emotion Regulation Questionnaire (ERQ) reappraisal subscale (Gross & John, 2003). |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Mindfulness (FFMQ-15) |
Five Facet Mindfulness Questionnaire - 15 (FFMQ-15; Baer et al., 2006). |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Subjective cognitive function (PDQ-D) |
Perceived Deficits Questionnaire - Depression (PDQ-D; Fehnel et al., 2016) |
Development from pre-treatment to post-treatment and development from pre-treatment through 3-month follow-up |
|
Secondary |
Experience of therapy |
Five questions concerning the participants' experience or expectations concerning the components have been developed by the project group due to a lack of such assessment in the field. |
Session by session development during the 6 weeks of active treatment and through 3-month follow-up |
|
Secondary |
Working alliance (WAI-SR) |
Working Alliance Inventory - Short Revised (WAI-SR; Munder et al., 2010). |
Session 3 and 5 only |
|
Secondary |
Information overload (IO) |
The Information Overload (IO) scale, consisting of 8 items. This is our own adaptation of the Cancer Information Overload scale (Jensen et al., 2014) to assess perceived information overload related to the received treatment. This is included in all session questionnaires. |
Session by session development during the 6 weeks of active treatment |
|